Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Defining the role of cytomegalovirus in glioblastoma therapies

Award Number: R01CA263324
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/11/2022
PERIOD OF PERFORMANCE END DATE: 03/31/2027
AWARD TERMINATION DATE: 04/29/2025

Group Awards By:

View Award Description

Defining the role of cytomegalovirus in glioblastoma therapies - Project Summary/Abstract Glioblastoma (GBM) is an incurable brain tumor for which improved therapies are badly needed. There are roughly 10,000 cases diagnosed in the US each year, and median survival is ~14 months. Evidence has been accumulating over recent years linking cytomegalovirus (CMV) to GBM and other cancers. However, the role of CMV in GBM remains poorly defined. CMV is a prevalent virus in humans, where it resides lifelong in a latent state but can be reactivated under certain conditions. Several clinical trials targeting CMV using diverse approaches including immunotherapies and the anti-viral drug CMV have shown very promising responses in GBM patients, but the underlying mechanisms are not clear. To improve our understanding of this area we have developed an immunocompetent murine model of intracranial GBM grown in the context of a systemic latent CMV infection. This consistently leads to significantly shortened survival compared with mock infected controls in multiple distinct murine GBM models. These effects can be reversed by treatment with anti-viral drugs. Our new preliminary human data shows reduced progression free survival in CMV seropositive humans and similarities in patterns of differentially expressed genes supporting the relevance of the mouse model. Our model features increased blood vessel formation, with accumulation of perivascular pericytes, increased CD8+ T cell infiltrates and resistance to chemotherapy. We discovered that platelet-derived growth factor-δ (PDGFD) is upregulated by CMV infection of tumor cells, and that CRISPR-mediated knockdown of PDGFD prevents pericyte recruitment and severely impairs tumor growth. Therefore in Specific Aim 1 we will further investigate PDGFD as a potential GBM therapeutic target. Also, we have preliminary data with a replication- defective viral mutant suggesting that CMV replication is critical to this phenotype, and we will use this mutant to explore the mechanisms by which CMV enhances tumor progression. We also have shown that the tumor microenvironment is significantly impacted by CMV, therefore in Specific Aim 2 we will examine the therapeutic implications of CMV on tumor/immune interactions, and the importance of viral replication in these effects. In Specific Aim 3 we will use our model to investigate the interactions of CMV with standard of care chemoradiation, in terms of viral reactivation and sensitization to therapies by anti-viral drugs. Results from the proposed experiments will bring us to a deeper understanding of the impact that CMV has on GBM progression, providing badly needed targets and rational therapeutic combinations for future clinical trials in this devastating disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $653,127 )
2026	2026	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	000	5	4/17/2026	NON-COMPETING CONTINUATION	$653,127
														Subtotal = $653,127

Issue Date FY: 2025 ( Subtotal = $653,127 )
2025	2025	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	000	4	3/3/2025	NON-COMPETING CONTINUATION	$587,814
2025	2025	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	002	4	7/8/2025	NON-COMPETING CONTINUATION	$65,313
2025	2024	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	001	3	4/28/2025	TERMINATION	$0
														Subtotal = $653,127

Issue Date FY: 2024 ( Subtotal = $705,346 )
2024	2024	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	003	3	4/18/2024	SUPPLEMENT FOR EXPANSION	$4,467
2024	2024	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	001	3	2/29/2024	SUPPLEMENT FOR EXPANSION	$80,408
2024	2024	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	002	3	4/17/2024	NON-COMPETING CONTINUATION	$32,659
2024	2024	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	000	3	2/28/2024	NON-COMPETING CONTINUATION	$587,812
														Subtotal = $705,346

Issue Date FY: 2023 ( Subtotal = $737,769 )
2023	2023	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	001	2	5/1/2023	SUPPLEMENT FOR EXPANSION	$89,342
2023	2023	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	000	2	4/28/2023	NON-COMPETING CONTINUATION	$648,427
														Subtotal = $737,769

Issue Date FY: 2022 ( Subtotal = $688,910 )
2022	2022	BROWN UNIVERSITY	1 PROSPECT ST	PROVIDENCE	RI	02912	PROVIDENCE	USA	Cancer Biology Research	000	1	4/11/2022	NEW	$688,910
														Subtotal = $688,910

Grand Total All Awards = $3,438,279

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the role of cytomegalovirus in glioblastoma therapies

Award Number: R01CA263324

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/11/2022

PERIOD OF PERFORMANCE END DATE: 03/31/2027

AWARD TERMINATION DATE: 04/29/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer